Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanotechnology: A Balm for the Challenges of Drug Delivery

This article was originally published in Start Up

Executive Summary

2007 was an awful year for drug delivery companies, and 2008 is shaping up to be no better. The share prices of many drug delivery companies are trading at or below their 10-year averages as investors realize that convenient delivery of large molecules that heretofore required painful injections isn't necessarily a compelling commercial opportunity. Still, intrepid venture capitalists are investing in some companies that are capitalizing on one key difference: these fledgling start-ups use nanotechnology to create therapies that are significantly different--especially in terms of safety and efficacy--from the first-generation drugs they hope to supplant.
Advertisement

Related Content

Another Twist in Myocet Plot With $55 Million Zoticon-Led Financing for Sopherion
FDA Ramps Up Data Gathering On How To Regulate Nanotech In Drugs, Biologics
FDA Seeks Public Input To Develop Guidance For Nanotechnology In Pharmaceuticals
Nanotechnology, Bioequivalence On Pharmaceutical Science Panel Agenda
Tempo Pharmaceuticals Inc.
TransGenex Nanobiotech Inc.
BIND Biosciences Inc.
Liquidia Technologies Inc.
Nanolymf Ltd.
Exubera's Problem: It's Still Just Insulin

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091573

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel